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OBJECTIVES: Therapies for dysmotility-like functional dyspepsia (FD) are limited. We studied tegaserod, a
selective serotonin type 4 receptor agonist, in patients with FD.
METHODS: Two identical multicenter, double-blind, randomized, placebo-controlled trials enrolled women ≥18
yr with recurring mid-upper abdominal discomfort characterized by postprandial fullness, early
satiety, and/or bloating. Patients were randomized to tegaserod 6 mg b.i.d. or placebo. Two
patient-reported primary variables were assessed: percentage of days with satisfactory symptom
relief, and symptom severity using the composite average daily severity score (CADSS).
RESULTS: In total, 2,667 women were randomized with no differences between trials in terms of recruitment
method, Helicobacter pylori status, heartburn, or medication use. Mean percentage of days with
satisfactory symptom relief for tegaserod versus placebo in Trial 1: 32.2% versus 26.6% (95% CI of
treatment difference 2.82, 9.27; P < 0.01), Trial 2: 31.9% versus 29.4% (95% CI of treatment
difference −0.21, 6.53; P = 0.066). Mean CADSS in Trial 1: 3.14 versus 3.35 (95% CI of treatment
difference −0.29, −0.10; P < 0.0001), Trial 2: 3.15 versus 3.23 (95% CI of treatment difference
−0.18, 0.01; P = 0.094). Meta-analysis showed significant benefit for both end points: increase in
days with satisfactory relief 4.6% (95% CI 2.29, 6.96); decrease in CADSS 0.14 (95% CI 0.21, 0.07).
Treatment effect was greater in patients with severe baseline symptoms. Diarrhea requiring study
discontinuation was more common with tegaserod than placebo (4.1% vs 0.3%).
CONCLUSIONS: Some improvement in dysmotility-like FD was observed with tegaserod treatment. The clinical
implication of this improvement is uncertain.
(Am J Gastroenterol 2008;103:1906–1919)
INTRODUCTION
Dyspepsia is a common disorder, experienced by approxi-
mately 25% of the general population in Western countries
(1). The cardinal manifestation is pain or discomfort centered
in the upper abdomen, which may be associated with other
upper gastrointestinal (GI) symptoms.
While some patients have a known cause for their dys-
pepsia (e.g., peptic ulcer, gastro-esophageal reflux disease
[GERD], or malignancy), others have no explanation despite
clinical testing. These patients are classified as having func-
tional dyspepsia (FD) (2, 3). FD can be subdivided based on
symptom characteristics. The ROME II Committee on Func-
tional Gastrointestinal Disorders recognized dysmotility-like
(discomfort centered in the upper abdomen, which may be
associated with meal-related symptoms such as postprandial
fullness, early satiety, bloating, or nausea) and ulcer-like (pain
centered in the upper abdomen as the predominant symptom)
subgroups of FD (2). The ROME III definition of FD distin-
guished a postprandial distress syndrome from an epigastric
pain syndrome (4).
While dyspepsia symptoms can impair numerous aspects
of patients’ daily activities and well-being, dysmotility-like
symptoms are reported to have the greatest negative impact
on health-related quality of life (HRQoL) (5, 6). A single
causative mechanism for FD symptoms has not been defined,
although several abnormalities in upper GI sensory and mo-
tor function have been reported (4, 7–11). Given the absence
of a distinct, single pathophysiologic mechanism for FD and
the diversity of symptoms, it is likely that different patient
subgroups may require different management approaches
(4).
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Current therapy for FD is limited and largely consists of
empirical treatment with proton pump inhibitors (PPIs) and
eradication of Helicobacter pylori infection (12, 13). While
these approaches can offer benefit to some patients with
ulcer-like FD or symptoms of coexisting GERD, treatment
results are variable (14–16). Furthermore, no currently avail-
able agent has been documented to improve dysmotility-like
FD.
Tegaserod, a selective serotonin type 4 receptor agonist, is
an effective treatment for irritable bowel syndrome with con-
stipation (IBS-C) and chronic idiopathic constipation (17–
21). Tegaserod has been shown to improve gastric and small
intestinal motility by normalizing delayed gastric empty-
ing, enhancing gastric accommodation, and improving im-
paired antroduodenal motility (4, 22–27). Tegaserod may
also decrease visceral hypersensitivity (28, 29). Pilot stud-
ies suggest that tegaserod can improve dysmotility-like FD
symptoms in women (24, 30). These data provided the ratio-
nale to investigate further the potential value of tegaserod in




The two multicenter, double-blind, randomized, placebo-
controlled trials (ClinicalTrials.gov NCT00232024 [Trial 1]
and NCT00232089 [Trial 2]) were conducted between Jan-
uary 2004 and June 2006 at 675 sites in the United States,
United Kingdom, Canada, and South Africa. The trials were
of identical design. Both comprised a 4-wk screening period,
a 2-wk baseline period, and a 6-wk treatment period (Fig. 1)
Figure 1. Study design. ∗Upper GI endoscopy was performed to exclude patients with gastric, esophageal, or duodenal abnormalities unless
the patient had a normal endoscopy in the preceding 24 wk.
and were developed according to recommendations made by
the ROME II committee (2).
Randomization and Concealed Allocation
Patients were assigned randomly to tegaserod 6 mg twice
daily (b.i.d.) or placebo; both treatments were identical
in appearance. Randomization (1:1 allocation ratio) was
performed using a computer-generated sequence in each
treatment center using permutated blocks of size 4. The
randomization scheme was reviewed by a biostatistics qual-
ity assurance group, locked on their approval, and concealed
from patients and study personnel at both the site and the
sponsor offices until after both trials were completed.
Patient Population
Patients were English-speaking women ≥18 yr of age with
recurring mid-upper abdominal discomfort characterized by
at least two of the following symptoms: postprandial fullness,
early satiety, and/or bloating. Symptoms had to be present for
at least 12 wk, not necessarily consecutive, during the pre-
vious 12 months. Thus, symptom characteristics were com-
patible with dysmotility-like FD, as defined by the ROME II
Committee (2).
Key exclusion criteria included a history of erosive
esophagitis, erosive gastroduodenitis, gastric or duodenal ul-
ceration (confirmed by negative upper GI endoscopy during
screening); previous abnormal 24-h esophageal pH metry
assessment; complaint of their most bothersome symptom
being heartburn, nausea, or vomiting, or epigastric/ulcer-like
pain; frequent heartburn (>2 times per week); current IBS or
IBS-like symptoms; use of antisecretory or prokinetic med-
ications; and concomitant serious medical conditions. Also,
pregnant or breastfeeding women and those of childbearing
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Table 1. Questions on Dyspepsia Symptoms
Verbatim Question Explanation Given to Patients
Daily Individual Symptom Questions:
. . .early fullness while
eating?
Early fullness while eating is a feeling the stomach is
uncomfortably full soon after starting a normal size
meal so that it is difficult to finish the meal
. . .postmeal fullness? Postmeal fullness is an uncomfortable feeling of being
overly full after a meal
∗How much discomfort have you had today
from. . .
. . .bloating? Bloating is an uncomfortable feeling of tightness or
pressure in the stomach or belly like it is swollen;
clothing may feel too tight on the stomach or belly,
which could appear visibly larger or distended
. . .abdominal pain? No explanation given
. . .nausea? Nausea is a sick feeling as if you were going to vomit
or throw-up
Did you have any occurrence of vomiting
today?
No explanation given
Daily Satisfactory Relief Question:
†Today did you have satisfactory relief of your
mid-upper abdominal discomfort, which
may include early fullness while eating,
postmeal fullness, or bloating?
Satisfactory relief means your dyspepsia symptoms
were not bothersome today
Weekly Global Assessment of Change Question:
‡Compared with how you felt prior to entering
this study, how would you rate your
dyspepsia symptoms during the last week?
No explanation given
CADSS = composite average daily severity score.
∗1 = no discomfort at all, 2 = minimal discomfort, 3 = mild discomfort, 4 = moderate discomfort, 5 = moderately severe discomfort, 6 = severe discomfort, 7 = very severe
discomfort.
†Yes/No.
‡3 = a lot better, 2 = better, 1 = a little better, 0 = unchanged, −1 = a little worse, −2 = worse, −3 = a lot worse.
age who were not using an approved method of contraception
were excluded.
During the 2-wk observational baseline period and the 6-
wk treatment period, patients rated the discomfort caused by
their dyspepsia symptoms (postprandial fullness, early sati-
ety, bloating, abdominal discomfort/pain, and nausea) on a
7-point Likert scale (1 = no discomfort to 7 = very severe dis-
comfort). This was done each day using an interactive voice
response system. On a weekly basis, patients completed the
Global Assessment of Change question, rating any change in
their dyspepsia symptoms on a 7-point Likert scale (−3 =
a lot worse to 3 = a lot better) (Table 1). The descriptions
of the dyspepsia symptoms were developed and tested with
FD patients (N = 74) prior to initiating the trials in order
to ensure that the medical terms used were understandable
(Table 1) (31). During the baseline observation period, pa-
tients who reported an average of at least “mild discomfort”
(≥3 on a 7-point Likert scale) for two or more of the cardi-
nal dyspepsia symptoms (postprandial fullness, early satiety,
and bloating), who responded “no” ≥50% of the time to the
daily satisfactory relief question (Table 1), and who recorded
an assessment of their symptoms on ≥11 of 14 days, were
eligible for randomization.
Efficacy Assessments
Two patient-assessed primary variables were used: (a)
percentage of days with satisfactory relief of dyspepsia
symptoms, and (b) composite average daily severity score
(CADSS) for the three cardinal dyspepsia symptoms (post-
prandial fullness, early satiety, and bloating). CADSS was
calculated by averaging the responses to the daily questions
regarding individual dyspepsia symptom severity (Table 2).
This composite end point had not been validated formally
prior to the trials commencing. These primary variables were
based on recommendations made in 2000 by the ROME II
Committee (2). The secondary variables are listed and de-
scribed in Table 2.
HRQoL
The impact of study medication on patients’ HRQoL was
assessed using the Short Form-36 Nepean Dyspepsia Index
questionnaire (SF-NDI), a validated, disease-specific HRQoL
measure (32, 33). SF-NDI comprises five domains (tension,
interference with daily activities, eating/drinking, knowl-
edge/control, and work/study), with each domain comprising
two items. Patients rated each item, recalling the previous
2 wk, on 5-point Likert scales, providing individual do-
main scores ranging from 2 to 10. SF-NDI was adminis-
tered at baseline, week 3 of study medication, and at end of
treatment.
Tolerability and Safety Assessments
All adverse events (AEs) and serious AEs (SAEs, i.e., a med-
ically significant event that was life-threatening, required
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Table 2. Efficacy Variables
Efficacy Variable Assessment
Primary Variables:
Percentage of days with satisfactory relief of dyspepsia symptoms Responded “Yes” to the daily satisfactory relief question
CADSS of postprandial fullness, early satiety, and bloating Based on responses to the daily questions on individual
symptoms∗
Secondary Variables:
Overall and weekly responder rates for percentage of days with
satisfactory relief
Responded “Yes” to the daily satisfactory relief question
≥50% of the time
Overall and weekly responder rates for CADSS ≥1.0 point improvement from baseline∗
Overall and weekly responder rates for individual symptom severity
scores for early satiety, postprandial fullness, bloating, and nausea
≥1.0 point improvement from baseline∗
Overall and weekly responder rates for global assessment of change in
dyspepsia symptoms
Responded “Better” or “A lot better” to the global
assessment of change question†
CADSS = composite average daily severity score.
∗1 = no discomfort at all, 2 = minimal discomfort, 3 = mild discomfort, 4 = moderate discomfort, 5 = moderately severe discomfort, 6 = severe discomfort, 7 = very severe
discomfort.
†Global assessment of change question responses: 3 = a lot better, 2 = better, 1 = a little better, 0 = unchanged, −1 = a little worse, −2 = worse, −3 = a lot worse.
hospitalization, or caused significant incapacity) were
recorded. In addition, vital signs, hematology, urinalysis,
blood chemistry, and electrocardiograph data were evaluated.
Stool frequency and form, using the Bristol Stool Scale, were
recorded daily (34). Patients were withdrawn from the trials
if they interrupted study medication for >5 consecutive days,
and reasons for patient dropout were recorded.
Statistical Analysis
Target enrollment for each trial was 1,296 (648 per treatment
arm) patients per trial. This was calculated using a Bonfer-
roni adjustment for type 1 errors to detect a 10% difference
between tegaserod and placebo groups with 90% power, as-
suming a 30% placebo response rate. The decision to power
the study to detect a 10% difference was based on results
from the phase II FD studies with tegaserod, and by the min-
imal level of improvement suggested by clinicians involved
in designing the trials and considered necessary for indica-
tion approval by Health Authorities. Efficacy outcomes were
analyzed in the intention-to-treat (ITT) population of all ran-
domized patients. AEs were evaluated in all patients who
received at least one dose of study medication (safety ana-
lyzable population).
Data from each trial were analyzed separately. Primary
efficacy variables were evaluated over the entire treatment
period using analysis of covariance (ANCOVA) models that
included treatment, baseline measurements, and pooled treat-
ment center as variables. Hochberg’s procedure was used to
control for a type 1 error rate of 5%. Treatment effects (dif-
ferences in least square means [LSM]) and 95% confidence
intervals (CIs) were obtained for each variable. Predefined
nonparametric sensitivity analyses were conducted to evalu-
ate the robustness of data, i.e., skewness and outliers. As the
percentage of days data were skewed right, median data are
provided in addition to mean data.
For each variable, three predefined response criteria were
evaluated: ≥50%, ≥66%, and ≥75% of days with satisfac-
tory symptom relief; and ≥1-point, ≥1.5-point, and ≥2-point
improvements from baseline for CADSS and for change in
individual symptoms. Results for ≥50% of days with satis-
factory relief and ≥1-point improvement from baseline for
CADSS and individual symptoms are reported in this article.
Response was analyzed using logistic regression models with
treatment, baseline symptom score, and pooled center as co-
variates. Change in global assessment of dyspepsia symptoms
was evaluated using Mantel-Haenszel tests. SF-NDI domain
scores were analyzed using ANCOVA models including treat-
ment, baseline measurements, and pooled treatment center as
variables.
Interactions between treatment results and various baseline
factors were analyzed within each trial for each primary effi-
cacy variable. In addition, the data were pooled in a post hoc,
patient-level, meta-analysis and reanalyzed to provide the
best estimates of treatment effects and to test for interaction
between treatment and baseline disease and demographic fac-
tors (including study). These meta-analyses were performed
using models identical to those used within each study and by
including a factor to account for study variability. A signifi-
cant interaction (P = 0.0060) between treatment and baseline
CADSS was identified for the CADSS primary variable. To
investigate this treatment interaction further, patients were
subgrouped arbitrarily according to baseline symptom sever-
ity: mild (CADSS 1 to <4), moderate (CADSS 4 to <5),
severe (CADSS 5–7).
The study protocols were approved by ethics committees
at all participating centers and performed according to the
Declaration of Helsinki and the principles of Good Clinical
Practice. All patients gave written informed consent.
RESULTS
Patient Characteristics
Patient disposition is summarized in Figure 2. The most fre-
quent reasons for exclusion prior to randomization were fail-
ure to meet the diagnostic criteria (e.g., presence of GERD or
erosive gastritis or duodenitis) and dyspepsia symptoms that
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Figure 2. Summary of patient flow. ∗Discontinuations are shown for the screening and baseline phases combined. A patient may have more
than one reason for not continuing into the randomization phase. AEs = adverse events; ITT = intention-to-treat.
did not meet the severity criteria during the baseline period.
Most randomized patients (1,134 [84.8%] tegaserod, 1,185
[89.1%] placebo) completed the trials. Patients randomized
to placebo or tegaserod had similar demography, body mass
index, and symptom scores at baseline. Prior use of medica-
tion was similar between treatment groups and the individual
studies at baseline. The medications most commonly used by
patients prior to the trials were PPIs (Trial 1: 11.4% tegaserod
vs 15.3% placebo; Trial 2: 10% tegaserod vs 10.1% placebo)
and H2 receptor antagonists (Trial 1: 5.3% tegaserod vs 5.3%
placebo; Trial 2: 3.5% tegaserod vs 4.1% placebo).
Patients were recruited into the trials from a variety of
sources. Most were recruited from print, radio, or TV ad-
vertisements (Trial 1: 48%, Trial 2: 51%) or from the study
investigators’ own practices (Trial 1: 30%, Trial 2: 27%). Re-
ferral directly from physicians who were not investigators for
the study accounted for ≤10% of recruitment across Trial 1
and Trial 2. Of these referrals, a majority were from primary
care (Trial 1: 30%, Trial 2: 27%) rather than tertiary care
(Trial 1: 10%, Trial 2: 6%).Tests for interaction revealed no
association between source of patient recruitment and treat-
ment outcome.
Approximately 80% of patients reported <1 day with
satisfactory relief during the 14-day baseline observation
period, the mean baseline CADSS scores were identi-
cal across treatment groups and trials and most patients
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Table 3. Patient Baseline Demographic Characteristics and Dyspepsia Symptom Scores (ITT Population)
Trial 1 Trial 2
Parameter Tegaserod 6 mg b.i.d. Placebo Tegaserod 6 mg b.i.d. Placebo
N 685 675 652 655
Age (mean ± SD), yr 43.7 ± 13.2 44.2 ± 14.5 43.4 ± 13.7 43.6 ± 13.2
Range, yr 18–80 18–87 18–85 18–82
Ethnic Origin, N (%)
White 537 (78.4) 524 (77.6) 510 (78.2) 511 (78.0)
Black 81 (11.8) 67 (9.9) 69 (10.6) 68 (10.4)
Asian 5 (0.7) 8 (1.2) 7 (1.1) 13 (2.0)
Other 62 (9.1) 76 (11.3) 66 (10.1) 63 (9.6)
BMI (mean ± SD), kg/m2 27.5 ± 6.6 27.6 ± 6.7 27.2 ± 6.2 27.2 ± 6.5
Range, kg/m2 16.5–62.1 15.5–58.0 15.2–62.4 16.1–63.4
Measurements at Baseline (mean ± SD)
Percentage of days with satisfactory relief 6.6 ± 12.3 7.1 ± 13.5 5.9 ± 11.2 6.6 ± 12.0
Mean CADSS∗ 4.3 ± 0.9 4.3 ± 0.9 4.3 ± 0.9 4.3 ± 0.9
Missing values are excluded from the table.
∗CADSS = composite average daily severity score (1 = no discomfort at all, 2 = minimal discomfort, 3 = mild discomfort, 4 = moderate discomfort, 5 = moderately severe
discomfort, 6 = severe discomfort, 7 = very severe discomfort); b.i.d. = twice daily; BMI = body mass index; ITT = intention-to-treat; SD = standard deviation.
reported dyspepsia symptoms of at least moderate severity
(Table 3).
Primary Efficacy Variables
Patients receiving tegaserod experienced a greater mean per-
centage of days with satisfactory symptom relief during the 6-
wk treatment period compared with those receiving placebo.
This treatment difference was statistically significant (32.2%
vs 26.6%, 95% CI of treatment difference 2.82, 9.27; P =
0.0002) in Trial 1, but not in Trial 2 (31.9% vs 29.4%,
95% CI of treatment difference −0.21, 6.53; P = 0.066)
(Table 4). In view of the skewed distribution of data for per-
centage of days with satisfactory relief, the median data are
also presented for tegaserod and placebo, respectively: Trial
1: 25.3% and 9.8% (P = 0.0004), Trial 2: 22.5% and 15.4%
(P = 0.0633).
Mean CADSS reported by tegaserod patients during the
treatment period (3.14) was significantly lower than that of
placebo patients (3.35) in Trial 1 (95% CI of treatment differ-
ence −0.29, −0.10; P < 0.0001), but not in Trial 2 (tegaserod
3.15 vs placebo 3.23, 95% CI of treatment difference −0.18,
0.01; P = 0.094) (Table 4).
The results of a post hoc, patient-level, meta-analysis us-
ing primary efficacy variable data from Trial 1 and Trial 2 are
shown in a petogram (Fig. 3). Also shown are the 95% CIs
relating to the two individual trials. When the data from both
trials were combined, the 95% CIs around the point estimates
were narrowed relative to each individual trial and the dif-
ferences were statistically significant for both primary vari-
ables: mean percentage of days with satisfactory symptom
relief (95% CI of treatment difference of 2.29, 6.96), mean
CADSS (95% CI of treatment difference −0.21, −0.07).
Secondary Efficacy Variables
RESPONDER RATE: PERCENTAGE OF DAYS WITH
SATISFACTORY RELIEF. The responder rate for percent-
age of days with satisfactory relief (≥50%) was significantly
greater with tegaserod than placebo (32.5% vs 25.9%; OR
1.45, 95% CI 1.13, 1.85; P = 0.003) in Trial 1, but not in
Trial 2 (tegaserod 32.0%, placebo 30.8%; OR 1.10, 95% CI
0.86, 1.41; P = 0.430).
RESPONDER RATE: COMPOSITE AVERAGE DAILY
SEVERITY SCORE. In Trial 1 there were significantly more
responders (change ≥1.0-point improvement in the sever-
ity of patients’ symptoms from baseline) to tegaserod than
placebo, as assessed by CADSS (49.9% vs 41.9%; OR 1.42,
95% CI 1.14, 1.77; P = 0.002). In contrast, while the respon-
der rate to tegaserod was numerically greater than placebo in
Trial 2, the difference was not statistically significant (50.3%
vs 45.8%; OR 1.21, 95% CI 0.97, 1.51; P = 0.092).
INDIVIDUAL DYSPEPSIA SYMPTOMS. Tegaserod re-
duced the severity of all individual symptoms of dyspepsia.
The response rate (≥1.0-point improvement from baseline)
was significant for all symptoms (early satiety [P = 0.001],
postprandial fullness [P = 0.0001], bloating [P = 0.002], ab-
dominal pain [P = 0.027], and nausea [P = 0.014]) in Trial
1, but only for postprandial fullness in Trial 2 (P = 0.04)
(Fig. 4).
GLOBAL ASSESSMENT OF CHANGE IN DYSPEPSIA
SYMPTOMS. In 5 out of the 6 wk in Trial 1 and in all 6 wk
in Trial 2, tegaserod was statistically superior to placebo (Fig.
5) for improving the patients’ rating of global change in dys-
pepsia symptoms (improvement was defined as a response of
“a lot better” or “better” on the 7-point Likert scale) compared
with baseline (Trial 1 P < 0.001, Trial 2 P = 0.004).
As described earlier, results for ≥50% of days with satis-
factory relief and ≥1-point improvement from baseline for
CADSS and individual symptoms are reported here; how-
ever, results using the other predefined responder definitions













































































































































































































































































































































































































































































































































(≥66% and ≥75% of days with satisfactory relief, and ≥1.5-
point, and ≥2-point improvement from baseline for CADSS
and individual symptoms) did not alter the overall response
picture (data not shown).
Treatment Response in Relation to Baseline Dyspepsia
Symptom Severity
Analyses of pooled data suggested that the treatment effect
of tegaserod may be greater in patients who had more se-
vere dyspepsia symptoms at baseline. Tegaserod provided
the greatest improvement in percentage of days with satis-
factory relief of symptoms in patients who reported severe
baseline symptoms (treatment effect −6.7% vs placebo; P =
0.01) compared with patients whose baseline symptoms were
rated as only moderate (treatment effect −2.4% vs placebo;
P = 0.075) or mild (treatment effect −4.2% vs placebo; P =
0.02).
Treatment with tegaserod also provided the greatest im-
provement in CADSS in patients who reported severe symp-
toms of dyspepsia at baseline: severe (treatment effect −0.28;
P = 0.005), moderate (treatment effect −0.12; P = 0.012),
and mild (treatment effect −0.07; P = 0.105).
The effect of tegaserod treatment on improving individual
symptoms was also most pronounced for those patients who
reported severe symptoms at baseline. A greater proportion of
these patients experienced a reduction in severity (≥1.0-point
improvement from baseline) with tegaserod versus placebo.
Improvement in four of the five dyspepsia symptoms (post-
prandial fullness, bloating, abdominal pain, and nausea) was
significantly greater with tegaserod compared with placebo
in these patients (P ≤ 0.016) while only postprandial fullness
had a significantly higher response with tegaserod among
patients with mild baseline symptoms (Table 5).
When baseline data were pooled, HRQoL domain scores,
as assessed by the SF-NDI, were comparable for tegaserod
and placebo patients within each symptom severity subgroup
and were comparable to other studies investigating the effect
of FD symptoms on sufferers’ QoL (5). All five SF-NDI do-
main scores were highest in patients who reported severe
baseline dyspepsia symptoms (P < 0.0001), indicative of
greatest impairment of all the measured aspects of HRQoL
(tension, interference with daily activities, eating/drinking,
knowledge, work/study). Importantly, the treatment benefit
with tegaserod for all five SF-NDI domains was greatest in
those patients with severe baseline dyspepsia symptoms. In
relation to HRQoL symptom domains that might be expected
to be adversely affected by dyspepsia, the greatest improve-
ment during tegaserod versus placebo therapy was observed
in the eating/drinking domain for this subgroup of patients
(0.77 point, P = 0.0005).
Treatment Exposure, Safety, and Tolerability
Exposure to study medication was high; approximately 87%
of patients reported ≥42 days of exposure to tegaserod or
placebo, consistent with the 6-wk treatment duration.
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Figure 3. Petogram illustrating confidence intervals for the two primary efficacy variables (percentage of days with satisfactory relief of
dyspepsia symptoms and mean CADSS) for both trials and for the meta-analysis (point estimates are shown between each set of confidence
intervals). P values for meta-analysis data: satisfactory relief of dyspepsia symptoms P = 0.0001; mean CADSS P < 0.0001.
During treatment with study drug, the most commonly re-
ported AEs in both trials were diarrhea, headache, and nau-
sea. Only diarrhea was more common with tegaserod than
with placebo treatment (Table 6). Significantly more patients
treated with tegaserod than placebo discontinued the study
because of diarrhea (54/1330 [4.1%] vs 4/1328 [0.3%]; P <
Figure 4. Proportion of patients with ≥1-point improvement from baseline in individual symptom severity scores. Symptoms were assessed
on a 7-point scale: 1 = no discomfort at all, 2 = minimal discomfort, 3 = mild discomfort, 4 = moderate discomfort, 5 = moderately
severe discomfort, 6 = severe discomfort, 7 = very severe discomfort  represents treatment differences between tegaserod and placebo
with confidence intervals included in parentheses below.
0.001). Of note, when analyzed by baseline symptom sever-
ity, more discontinuations because of diarrhea in tegaserod-
treated patients occurred in the mild/moderate rather than se-
vere dyspepsia symptom subgroups (mild 22/579 [3.8%] vs
moderate 24/485 [4.9%] vs severe 7/265 [2.6%]). SAEs were
reported by four patients (0.6%) in each treatment group of
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Figure 5. Proportion of patients with a response of “better” or “a lot better” on global assessment of change in dyspepsia symptoms.
“Compared with how you felt prior to entering this study, how would you rate your dyspepsia symptoms during the last week?” (3 = a lot
better, 2 = better, 1 = a little better, 0 = unchanged, −1 = a little worse, −2 = worse, −3 = a lot worse.). Response defined as “better” or
“a lot better”. ∗P ≤0.05, ∗∗P ≤0.001 tegaserod versus placebo.
Trial 1, and by two tegaserod patients (0.3%) and five placebo
patients (0.8%) in Trial 2. No deaths and no cases of ischemic
colitis were reported.
There was one AE in Trial 1 initially reported as a cardio-
vascular event. A 35-yr-old woman randomized to placebo
reported chest pain on Day 14 of the double-blind treatment
period. She was evaluated in the emergency room and in-
vestigations were negative for a cardiovascular event. This
patient completed the trial. There were two SAEs reported as
cardiovascular events in Trial 2. One case, later determined
to be musculoskeletal chest pain, occurred in a patient tak-
ing tegaserod, and one case of chest discomfort occurred in a
patient taking placebo. Both patients discontinued the study
prematurely.
DISCUSSION
The term “dyspepsia” defines a set of symptoms commonly
observed in primary care and has been estimated to account
for 2–5% of all family practice consultations (12). Most of
these patients have no identifiable explanation for their symp-
toms, and hence are described as having FD. The manage-
ment of FD can be both expensive and unsatisfactory because
Table 5. Improvement (≥1.0 Point) in Individual Symptoms by Baseline Symptom Severity∗ (Pooled Data)
Mild Moderate Severe
Response (%) Tegaserod P Tegaserod P Tegaserod P
(≥1.0-point) 6 mg b.i.d. Placebo Value 6 mg b.i.d. Placebo Value 6 mg b.i.d. Placebo Value
Early satiety 38.8 35.2 0.229 56.5 49.2 0.009 63.1 55.1 0.065
Postprandial fullness 45.9 39.4 0.031 56.1 48.4 0.013 65.8 54.0 0.005
Bloating 39.5 35.0 0.108 52.0 44.6 0.030 60.8 49.4 0.009
Abdominal pain 31.2 31.8 0.776 49.5 44.6 0.046 64.3 54.0 0.016
Nausea 16.9 14.3 0.096 30.0 27.2 0.092 48.3 36.2 0.009
∗Severity definition for composite average daily severity score (CADSS): mild (CADSS 1 to <4), moderate (CADSS 4 to <5), severe (CADSS 5–7).
treatment options are limited and symptom patterns do not
correlate well with pathophysiological abnormalities (12).
For example, while the use of prokinetic agents in patients
with dysmotility-type FD symptoms may lead to improve-
ment in delayed gastric emptying, there is little correlation
between changes in gastric emptying and symptom improve-
ment (35). Predictors of response to treatment are also prob-
lematic, making it difficult for clinicians and investigators to
identify patients who are likely to respond to treatment in
general or to a specific therapeutic approach based on their
presenting symptoms (36).
Other treatment approaches for FD include eradication of
H. pylori, and acid inhibition with PPIs (13, 37). However,
both H. pylori eradication and PPIs have limited efficacy
in FD, with randomized trials indicating that, as compared
with placebo, approximately one of every 15 patients receiv-
ing active therapy reports improvement in symptoms (38,
39). Furthermore, PPIs are no more effective than placebo
in patients with dysmotility-type FD (40). Because of the
limited efficacy of H. pylori eradication and acid inhibi-
tion in patients with dysmotility-type FD, a large propor-
tion of patients remain symptomatic with current treatment
approaches.
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Table 6. Frequency of Adverse Events (≥3% in Any Group), and Analysis of Diarrheal Episodes
Trial 1 Trial 2
Adverse Event Tegaserod 6 mg b.i.d. Placebo Tegaserod 6 mg b.i.d. Placebo
N 681 674 649 654
AE Frequency, N (%)
Diarrhea 129 (18.9) 26 (3.9) 125 (19.3) 34 (5.2)
Headache 40 (5.9) 27 (4.0) 30 (4.6) 33 (5.0)
Nausea 29 (4.3) 33 (4.9) 28 (4.3) 31 (4.7)
Abdominal pain 16 (2.3) 18 (2.7) 21 (3.2) 10 (1.5)
Vomiting 9 (1.3) 20 (3.0) 12 (1.8) 13 (2.0)
Time to Onset of First Diarrhea Episode (Days)
Median 2.0 18.0 2.0 8.0
Range 1–47 1–48 1–42 1–45
Number of Diarrhea Episodes per Patient, N (%)
1 111 (16.3) 22 (3.3) 101 (15.6) 33 (5.0)
2 16 (2.3) 5 (0.7) 18 (2.8) 1 (0.2)
3 5 (0.7) 0 6 (0.9) 1 (0.2)
4 0 0 1 (0.2) 0
5 1 (0.1) 0 0 0
6 2 (0.3) 0 1 (0.2) 0
Classification of Diarrhea, N (%)
Mild diarrhea 62 (9.1) 15 (2.2) 64 (9.9) 24 (3.7)
Moderate diarrhea 45 (6.6) 7 (1.0) 48 (7.4) 9 (1.4)
Severe diarrhea 22 (3.2) 4 (0.6) 13 (2.0) 1 (0.2)
Diarrhea leading to discontinuation 22 (3.2) 1 (0.1) 33 (5.1) 3 (0.5)
Diarrhea as SAE 0 0 0 0
Diarrhea was defined as any AE with the following preferred terms: diarrhea, loose stools, loose bowel, watery stools, fecal incontinence, frequent bowel movements, gastroenteritis,
watery diarrhea. For episodes marked as “continuing” at study end, the last visit date is imputed as the end date of the diarrheal episode.
The results of this study demonstrated some improvement
in patients’ dysmotility-like FD symptoms and HRQoL fol-
lowing treatment with tegaserod, with a trend toward an en-
hanced response in patients with severe dysmotility symp-
toms at baseline. Based on the treatment response for the
primary variables, the effect of treatment with tegaserod was
statistically significant in Trial 1, but not in Trial 2. A pre-
specified analysis identified baseline symptom severity and
the presence of heartburn (both represented equally in the
patients of both trials) as affecting the response to treatment.
This analysis failed to identify any other differences between
Trial 1 and Trial 2 that may have modified response to treat-
ment. Furthermore, testing for heterogeneity revealed no dif-
ference between the two trials, a result that supported the
decision to combine the primary variable data from both tri-
als as part of a post hoc, patient-level, meta-analysis. The
results of the meta-analysis suggest that the “true” effect of
treatment with tegaserod lies between the results of Trial 1
and Trial 2. The meta-analysis demonstrated a statistically
significant result when data from the two trials were com-
bined. However, whether the observed effect would be clin-
ically meaningful for individual patients in a clinical setting
remains to be determined, particularly because the primary
variables have yet to be validated against recognized clini-
cally meaningful parameters. Nevertheless, it is important to
note that when treatment response is assessed by stratifying
patients according to their baseline symptom severity, the re-
sponse to treatment for most variables was consistent across
both Trial 1 and Trial 2. Furthermore, consistent treatment
differences favoring tegaserod were observed across most of
the primary and secondary variables including HRQoL. This
result supports the suggestion that while tegaserod may not be
an appropriate treatment for all patients with dysmotility-type
FD, there may be some patients, particularly those with severe
symptoms, who could benefit. Using a responder definition
of ≥1 point from baseline for CADSS, the number-needed-
to-treat (NNT) in this study was 9 for the FD patients with
severe symptoms, and 16 for the ITT population.
As with all drugs, the benefit of tegaserod must be weighed
against its side effects. Diarrhea was the principal side effect
in these studies, with approximately 4% of patients discon-
tinuing tegaserod because of diarrhea. Patients with severe
FD symptoms had lower discontinuation rates because of the
side effects and had the greatest potential to benefit from treat-
ment. However in patients with mild-moderate FD symptoms,
an acceptable balance between benefit and side effects may
be more difficult to achieve. The result of the meta-analysis
that is based on ITT data (i.e., all dropouts are considered
failures) suggests that for the group as a whole, some benefit
is seen with tegaserod.
As observed in most FD trials, our study had a high placebo
response rate. As also seen in this and prior FD trials, the mag-
nitude of symptom improvement was modest when compared
with that of drugs for other therapeutic areas where altering
the underlying pathophysiology is the goal, such as in GERD
where treatment with PPIs reduce esophageal acid exposure
(41).
While the underlying pathophysiology of FD symptoms
is incompletely understood, the mechanism(s) responsible
for a significant therapeutic response are also unresolved.
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Treatment strategies for improving dysmotility-type FD
symptoms have been directed at accelerating gastric empty-
ing, enhancing gastric accommodation to a meal, and chang-
ing meal-related gastric volume. However, such strategies
have had limited success. Tegaserod was chosen for study in
FD as several early mechanistic trials showed that in addi-
tion to stimulating gastric emptying and small bowel transit,
tegaserod also reduced hyperalgesia in the upper GI tract and,
in some patients, improved gastric accommodation (4, 22–
27). Some studies have shown that cisapride, a nonselective
serotonin type 4 receptor agonist, improves dysmotility-like
FD symptoms, but a recent meta-analysis suggested that the
benefit attributed to cisapride in this condition may, in part,
be related to publication bias (42). Other gastroprokinetic
agents such as the motilin receptor agonist, ABT-229, have
been unsuccessful in the treatment of FD (43). Another agent
that has been studied in dyspepsia is itopride, a dopamine D2
antagonist and acetylcholinesterase inhibitor that in healthy
people reduces postprandial gastric volume without acceler-
ating gastric emptying or significantly altering gastric motor
and sensory function (44, 45). Although itopride was effec-
tive in improving symptoms of FD and heartburn in a Phase
II trial, no significant improvement over placebo in reduction
of FD symptoms was observed in two subsequent Phase III
trials (46, 47).
At present there is no established outcome measure to eval-
uate treatment efficacy in dysmotility-like FD. This may result
from our limited understanding of the causes of the disorder
as well as limited knowledge of factors modifying symptom
severity and related impact on patients. Recently, there has
been a new focus on prospectively determining such param-
eters. In 2007, the U.S. FDA mandated the use of validated,
patient-reported outcome (PRO) measures when assessing
symptom improvement in conditions like FD (48). The most
appropriate PROs for use in dyspepsia trials have not been
defined. In this study we used several end points, all of which
were PRO measures and recommended by the ROME II ex-
pert group (2). The advantage of the binary satisfactory relief
variable is that it has been well studied in IBS trials. However,
it may fail to capture more subtle degrees of improvement in
upper GI symptoms. While the CADSS assessment may cap-
ture changes in selected FD symptoms, the equal weighting of
individual symptom scores and the omission of other symp-
toms may have limitations. When symptoms are strongly cor-
related, considering them separately and assigning each an
equal weight may lead to overrating, a problem that would
not occur if the symptoms occurred independently of each
other. Furthermore, the CADSS scale has neither been val-
idated nor has the minimum clinically important difference
been determined for this scale. We have no information to in-
dicate that the small difference in CADSS between tegaserod
and placebo found in these studies is a clinically important
difference.
The most consistent improvements with tegaserod were
seen with the global assessment of change in individual dys-
pepsia symptoms during treatment compared with baseline.
This result was significant for both trials and for all weeks
except one. The main disadvantage of this variable is the in-
herent recall of pretreatment symptom severity, which may
lead to bias. However, this outcome variable closely resem-
bles the way treatment benefit is evaluated by physicians in
clinical practice. In light of the new guidance from the FDA
(48), additional evaluation of end points and validation stud-
ies will be required to determine the optimal outcome mea-
sure(s) for use in clinical trials assessing treatment effects in
dysmotility-like FD.
Because observed rates of treatment response have been
limited in all previous FD trials, it is reasonable to ask whether
better patient selection could improve the outcome of clin-
ical trials in FD. Because there is no unifying pathogenic
mechanism that explains the symptoms under evaluation,
and as improvements in some physiologic measures do not
readily translate into symptom improvement, patient selec-
tion on clinical grounds may need to be considered further.
In our study, exploratory analyses show that patients with
severe symptoms have a better response to tegaserod than
do patients with mild symptoms. To our knowledge, base-
line symptom severity has not been identified as an impor-
tant variable in previous FD treatment trials. Although these
symptom severity-related responses are viewed as hypothe-
sis generating and not confirmatory, future trials may benefit
from considering symptom severity in patient recruitment.
The strengths of our trials include the large sample size
and the careful selection of patients without symptoms or en-
doscopic findings of GERD, a problem that has complicated
previous trials in FD. Also, we did not attempt to control for
H. pylori status so the results stand alone and are not af-
fected by this consideration. The patient population we stud-
ied (those with dysmotility-type symptoms) has the greatest
need for an effective therapy because available treatments
are of limited or no efficacy (12, 13). Furthermore, the tri-
als were of identical design and there were no identifiable
differences between the trials in terms of patient character-
istics or demographics. A weakness is the inclusion of only
women. However, this choice was based on Phase II tegaserod
data that demonstrated greatest efficacy in women with dys-
pepsia symptoms and on the approval of tegaserod for use
only in women with IBS at the time the study program was
designed.
No cardiovascular toxicity was observed in tegaserod-
treated patients in either trial. The trials were completed be-
fore March 30, 2007, when Novartis announced it was com-
plying with a request from the FDA to suspend U.S. marketing
and sales of tegaserod owing to a potential signal suggesting
increased cardiovascular ischemic events with tegaserod use.
Obviously, the benefit versus the risk of any treatment choice
for dyspepsia, as well as for other conditions, needs to be
considered carefully.
In conclusion, the results from Trial 1 demonstrate that
tegaserod significantly improved some dyspepsia symptoms
in women with dysmotility-type FD, while a significant treat-
ment effect was not seen in Trial 2. A meta-analysis of
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the two trials shows a small statistically significant benefit
with tegaserod. The clinical importance of improvements in
FD symptoms of the magnitude seen in these trials is un-
certain. Any potential benefit with tegaserod appeared to
be most pronounced in those patients with severe baseline
symptoms.
FOOTNOTE
On March 30, 2007, Novartis complied with a request from
the Food and Drug Administration (FDA) to suspend U.S.
marketing and sales of Zelnorm (tegaserod maleate) because
the analysis of clinical trial data had identified a small im-
balance that was statistically significant in the number of
cardiovascular ischemic events in patients taking Zelnorm.
The data showed that events occurred in 13 out of 11,614
patients treated with Zelnorm (0.11%), compared with one
case in 7,031 placebo-treated patients (0.01%). These events
included heart attack, stroke, and unstable angina. These car-
diovascular ischemic events occurred in patients who had
preexisting cardiovascular disease and/or cardiovascular risk
factors. There is no demonstrated causal relationship between
Zelnorm and these events.
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STUDY HIGHLIGHTS
What Is Current Knowledge
 Treatment options for patients with dysmotility-like FD
are limited.
 Serotonergic agents modulate GI motility, secretion
and sensation.
 Tegaserod has been shown to improve the symptoms
of patients with IBS-C and CC.
What Is New Here
 Tegaserod improved some dysmotility-like FD symp-
toms in Trial 1 but the effect was not reproduced in
Trial 2.
 The greatest improvement in FD symptoms and
HRQoL with tegaserod occurred in patients with the
most severe symptoms.
 A meta-analysis of Trial 1 and Trial 2 results showed
that the “true” effect of treatment with tegaserod may
lie between the results of the individual trials.
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